Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 12/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 11/20 | 0.38 |
| ▸ | MBTD1 | Q05BQ5 | 6/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.32 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2003194 | 0.86 | L3MBTL3 (0.42) | HTR6L3MBTL3L3MBTL1MBTD1KMT2A | |
| SCHEMBL2004013 | 0.86 | L3MBTL3 (0.42) | HTR6L3MBTL3L3MBTL1MBTD1KMT2A | |
| SCHEMBL2003309 | 0.84 | L3MBTL3 (0.41) | HTR6L3MBTL3L3MBTL1MBTD1KMT2A | |
| SCHEMBL2006298 | 0.84 | L3MBTL3 (0.41) | HTR6L3MBTL3L3MBTL1MBTD1KMT2A | |
| SCHEMBL2006890 | 0.84 | L3MBTL3 (0.43) | HTR6L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL1892359 | 0.81 | HTR6 (0.57) | HTR6KMT2ASMN1; SMN2 | |
| SCHEMBL2572491 | 0.80 | KMT2A (0.39) | HTR6L3MBTL3L3MBTL1HPGDKMT2A | |
| SCHEMBL2009840 | 0.80 | L3MBTL3 (0.39) | HTR6L3MBTL3L3MBTL1MBTD1KMT2A | |
| SCHEMBL2007966 | 0.80 | L3MBTL3 (0.39) | HTR6L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL12730892 | 0.80 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1MBTD1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137939-A1 | INHIBITORS OF THE RAS ONCOPROTEIN, METHODS OF MAKING AND METHODS OF USE THEREOF | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137939-A1 | INHIBITORS OF THE RAS ONCOPROTEIN, METHODS OF MAKING AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | HTR6 4854/4885L3MBTL3 1301/4885L3MBTL1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.